Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 13 May, 2003

Xenova Group PLC

Research Update

Xenova Group PLC
13 May 2003


Xenova Group plc


    Xenova and QLT will continue to explore the potential of tariquidar and
          carefully review the data in order to plan future development

Slough, UK, 13 May, 2003 - Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) today announces that QLT Inc, (NASDAQ: QLTI; TSX: QLT) will stop
the current Phase III trials of tariquidar as an adjunctive treatment for
patients with non-small-cell-lung cancer (NSCLC). This decision follows a
recommendation by the Independent Data Safety Monitoring Committee (DSMC), which
completed the un-blinded interim review of the data for the two ongoing trials
in this indication. The Phase IIb trial for tariquidar in chemorefractory breast
cancer underway at MD Anderson, Texas is unaffected by this decision and this
trial continues.

Members of QLT's clinical development team will now be un-blinded so that they
have an opportunity to review all of the data and make informed decisions about
plans for the future development of tariquidar. Data from the 304 patients
already enrolled in this study represent the largest collection of efficacy and
safety data from a randomized, placebo-controlled study of a third generation
P-gp inhibitor and will offer valuable insight into the potential for tariquidar
in this or other indications. It is QLT's intention to exploit the value of this
database and make planning decisions for tariquidar after a thorough analysis of
such data.

David Oxlade, Chief Executive Officer of Xenova, said:

'Xenova continues to believe that tariquidar has potential as an MDR modulator
in cancer. We will explore further development opportunities once the un-blinded
data from these NSCLC studies have been assessed. The Phase IIb trial at MD
Anderson, in chemorefractory breast cancer continues.'

'Xenova has decided to take immediate steps to substantially reduce operating
costs. This will include a reduction in headcount as well as further programme
prioritisation. Going forward, Xenova will focus on its key clinical development

Conference Call Information

Xenova will hold a conference call on Tuesday, 13 May at 08:30 a.m. BST. For
details contact Claire Rowell at Financial Dynamics, telephone +44 (0) 20 7269

                                   -- ends --

UK:                                       US:
Xenova Group plc                          Trout Group/BMC Communications
Tel: +44 (0)1753 706600                   Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer   Press: Brad Miles (Ext 17) 
Daniel Abrams, Group Finance Director     Lauren Tortorete (Ext 20)
Jon Davies, Corporate Communications      Investors: Jonathan Fassberg (Ext 16) 
                                          Lee Stern (Ext 22)
Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors
Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders. Xenova has a broad pipeline of programmes
in clinical development. The Group has a well-established track record in the
identification, development and partnering of innovative products and
technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

About Tariquidar
Enrollment began in June 2002, for the two phase III clinical trials using
tariquidar as an adjunctive treatment in combination with first-line
chemotherapy for non-small-cell-lung cancer (NSCLC) patients. Approximately 1000
patients were to be enrolled in two randomized, multi-centred,
placebo-controlled trials using tariquidar in combination with two of the most
commonly used chemotherapy regimens (paclitaxel plus carboplatin or vinorelbine

The trials were conducted at roughly 100 centres located throughout North
America and Europe, and were designed to demonstrate the ability of tariquidar
to enhance the efficacy of chemotherapy agents. This occurs by preventing or
overcoming resistance due to over expression of P-glycoprotein (P-gp), a
membrane protein that pumps chemotherapeutic agents out of cancer cells.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors. For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission. We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange